BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1203890)

  • 1. Inhibition of Deamination of Arabinosylcytosine (NSC-63878) by Rhodium(II) Acetate.
    Lee SH; Chao DL; Bear JL; Kimball AP
    Cancer Chemother Rep; 1975; 59(3):661-3. PubMed ID: 1203890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alkylated cytosine nucleosides: substrate and inhibitor properties in enzymatic deamination.
    Krajewska E; Shugar D
    Acta Biochim Pol; 1975; 22(2):185-94. PubMed ID: 1098340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
    Chabot GG; Bouchard J; Momparler RL
    Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase.
    Marquez VE; Liu PS; Kelley JA; Driscoll JS; McCormack JJ
    J Med Chem; 1980 Jul; 23(7):713-5. PubMed ID: 7401098
    [No Abstract]   [Full Text] [Related]  

  • 5. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
    Laliberté J; Marquez VE; Momparler RL
    Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative reactivity of cytidine and arabinosylcytosine to their 6-methyl derivatives in the presence of cytidine deaminase.
    DeYoung JL; Notari RE; Feller DR
    Res Commun Chem Pathol Pharmacol; 1974 Sep; 9(1):163-72. PubMed ID: 4474681
    [No Abstract]   [Full Text] [Related]  

  • 7. On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.
    Wentworth DF; Wolfenden R
    Biochemistry; 1975 Nov; 14(23):5099-105. PubMed ID: 53069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phosphorus-containing pyrimidine analog as a potent inhibitor of cytidine deaminase.
    Ashley GW; Bartlett PA
    Biochem Biophys Res Commun; 1982 Oct; 108(4):1467-74. PubMed ID: 6758781
    [No Abstract]   [Full Text] [Related]  

  • 9. Deamination rates of 1-beta-D-arabinofuranosylcytosine, deoxycytidine and 5-methyl-2'-deoxycytidine in seven hematopoietic cell lines.
    Jekunen A
    Med Biol; 1987; 65(4):203-8. PubMed ID: 3437781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 1-beta-D-ribofuranosyl-1,2-dihydropyrimidin-2-one derivatives and their biological activities.
    Maeda M; Kaneko C; Uchida NA; Sasaki T
    Nucleic Acids Symp Ser; 1985; (16):77-80. PubMed ID: 4088888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and substrate specificity of human and canine cytidine deaminase.
    Fanucchi MP; Watanabe KA; Fox JJ; Chou TC
    Biochem Pharmacol; 1986 Apr; 35(7):1199-201. PubMed ID: 3964296
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size.
    Liu PS; Marquez VE; Driscoll JS; Fuller RW; McCormack JJ
    J Med Chem; 1981 Jun; 24(6):662-6. PubMed ID: 7252974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ara-C metabolism: implications for drug resistance and drug interactions.
    Chabner BA; Hande KR; Drake JC
    Bull Cancer; 1979; 66(1):89-92. PubMed ID: 420952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Escherichia coli cytidine deaminase by a phosphapyrimidine nucleoside.
    Ashley GW; Bartlett PA
    J Biol Chem; 1984 Nov; 259(21):13621-7. PubMed ID: 6386818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleosides. CXIX. Substrate specificity and mechanism of action of cytidine deaminases of monkey plasma and mouse kidney.
    Watanabe KA; Reichman U; Fox JJ; Chou TC
    Chem Biol Interact; 1981 Oct; 37(1-2):41-54. PubMed ID: 7285246
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA; Boothman DA; Greer SB
    Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymology of cytosine arabinoside.
    Cheng YC; Capizzi RL
    Med Pediatr Oncol; 1982; 10 Suppl 1():27-31. PubMed ID: 7162464
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance of cyclocytidine to cytidine deaminase.
    Hoshi A; Iigo M; Saneyoshi M; Kuretani K
    Chem Pharm Bull (Tokyo); 1973 Jul; 21(7):1535-8. PubMed ID: 4731230
    [No Abstract]   [Full Text] [Related]  

  • 19. Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides.
    Kelley JA; Driscoll JS; McCormack JJ; Roth JS; Marquez VE
    J Med Chem; 1986 Nov; 29(11):2351-8. PubMed ID: 3783592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The action of bacterial cytidine deaminase on 5,6-dihydrocytidine.
    Evans BE; Mitchell GN; Wolfenden R
    Biochemistry; 1975 Feb; 14(3):621-4. PubMed ID: 1090298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.